Fierce Pharma Biopharma News & Insights
Fierce Pharma delivers breaking news and analysis about drug companies, the FDA and the broader pharma industry, including manufacturing, marketing and finance.
2024 approvals: Biopharma delivered 55 new drugs, biologics
2025年1月2日 · The FDA signed off on 55 new drugs in 2024, down from 60-plus in 2023.
J&J's subcutaneous Rybrevant, AZ's Andexxa are rejected by FDA
2024年12月17日 · As for the FDA's rejection of Andexxa, the company said in an email that it will keep the treatment on the market in the U.S. AZ confirmed the CRL, which was reported last week by Pink Sheet.. In ...
Top 20 pharma companies by 2023 revenue - Fierce Pharma
There were changes at the top and the bottom of last year’s top 20 pharma rankings by revenue. And, in between, Novo Nordisk made a significant leap, jumping five spots propelled by skyrocketing ...
Trump won a second term. What does it mean for biopharma?
2024年11月6日 · On Tuesday night, millions of Americans watched as former president Donald J. Trump gathered up enough electoral votes needed to win the U.S. | Over his first term, Donald Trump advocated for ...
Top 10 most anticipated drug launches of 2024 | Fierce Pharma
2024年1月29日 · Every year, we tap Evaluate's annual preview report to assess the biggest potential new drugs of the year ahead. Typically, major pharmaceutical and biotechnology companies are featured, each ...
Compounders protest as FDA removes tirzepatide off shortage list
2024年12月19日 · The FDA has doubled down on its decision to remove Eli Lilly’s tirzepatide from its list of products that are in shortage. The agency’s move means that compounding pharmacies will have to halt ...
2024's Fiercest Women in Life Sciences - fiercepharma.com
2024年11月18日 · This year, like so many others, has been a bit of a mixed bag for women, and especially for those seeking positions of power. For the second time in the last decade, a woman—the U.S.’ first ...
Novo Nordisk wins hard-fought FDA approval for once-daily …
2024年12月23日 · Digging deeper into the data, the estimated average ABR for patients on Novo’s drug was 1.7 versus 11.8 for patients with no prophylaxis, while the respective median ABR was zero for treated ...
Big Pharma Companies Ranked by Revenue 2022 - Fierce Pharma
While a few companies continued to reap huge profits from COVID products in 2022, others benefited from a return to normalized business operations.